C-reactive protein (CRP), erythrocyte sedimentation rate (ESR) or both

Slides:



Advertisements
Similar presentations
Functional Analysis of the Neurofibromatosis Type 2 Protein by Means of Disease- Causing Point Mutations Renee P. Stokowski, David R. Cox The American.
Advertisements

2015 Alzheimer's disease facts and figures Alzheimer's & Dementia: The Journal of the Alzheimer's Association Volume 11, Issue 3, Pages (March.
High and increasing prevalence of inflammatory bowel disease in Finland with a clear North–South difference  Airi Jussila, Lauri J. Virta, Veikko Salomaa,
The requirements and barriers to successful transition of adolescents with inflammatory bowel disease: Differing perceptions from a survey of adult and.
Serta Kılınçalp, Akif Altınbaş, Ömer Başar, Murat Deveci, Osman Yüksel 
Volume 133, Issue 2, Pages (August 2007)
Does the endoscopic appearance of the ileocecal valve suggest the severity of Crohn's disease in the terminal ileum?  Tamás Molnár, Klaudia Farkas, Ferenc.
Concurrent small bowel adenocarcinoma and carcinoid tumor in Crohn's disease — Case report and literature review  Doron Boltin, Zohar Levi, Marisa Halpern,
Validation of a point-of-care desk top device to quantitate fecal calprotectin and distinguish inflammatory bowel disease from irritable bowel syndrome 
YouTube® and inflammatory bowel disease
A case report: Ulcerative colitis, treatment with an antibody against tumor necrosis factor (infliximab), and subsequent liver necrosis  Urpo Kinnunen,
Incidence of ulcerative colitis and Crohn's disease in Danish children: Still rising or levelling out?  Christian Jakobsen, Vibeke Wewer, Frederikke Urne,
Ineffectiveness of infliximab therapy in severe infantile Crohn's disease  Nuray Uslu, Yusuf Usta, Inci Nur Saltik-Temizel, Hulya Demir, Figen Gürakan,
Primary biliary cirrhosis developing in a patient with Crohn's disease during the course of infliximab treatment: The first case in the literature  Gurhan.
Preoperative use of anti-TNF therapy and postoperative complications in inflammatory bowel diseases: A meta-analysis  Vincent Billioud, Alexander C. Ford,
High and increasing prevalence of inflammatory bowel disease in Finland with a clear North–South difference  Airi Jussila, Lauri J. Virta, Veikko Salomaa,
Prevalence of irritable bowel syndrome (IBS) in first-degree relatives of patients with inflammatory bowel disease (IBD)  Mariam Aguas, Vicente Garrigues,
Validation of a point-of-care desk top device to quantitate fecal calprotectin and distinguish inflammatory bowel disease from irritable bowel syndrome 
Anterior ischemic optic neuropathy in a patient with Crohn's disease and aberrant MTHFR and GPIIIa gene variants  T. Felekis, K.H. Katsanos, C.D. Zois,
Serum prohepcidin levels in chronic inflammatory bowel diseases
Oral tacrolimus for pediatric steroid-resistant ulcerative colitis
Charlotte de Bie, Angelika Kindermann, Johanna Escher 
N. Kjaersgaard Nielsen, V. Wewer, L. Skafte, A. Paerregaard 
Fatal Colonic Perforation in a Pregnant with Behçet's Disease
Valle García-Sánchez, Eva Iglesias-Flores, Raúl González, Javier P
Familial aggregation in Crohn's disease and ulcerative colitis in a Norwegian population- based cohort followed for ten years  May-Bente Bengtson, Camilla.
Public awareness of Crohn's disease and ulcerative colitis: A national survey  Sieglinde Angelberger, Harald Vogelsang, Gottfried Novacek, Wolfgang Miehsler,
Validation of a point-of-care desk top device to quantitate fecal calprotectin and distinguish inflammatory bowel disease from irritable bowel syndrome 
B. Sicilia, F. Arribas, J. Nerín, C. López Miguel, R. Vicente, F
Incidence of ulcerative colitis and Crohn's disease in Danish children: Still rising or levelling out?  Christian Jakobsen, Vibeke Wewer, Frederikke Urne,
Activated thrombin activatable fibrinolysis inhibitor (TAFIa) is associated with inflammatory markers in inflammatory bowel diseases  Danuta Owczarek,
Canadian cost-utility analysis of initiation and maintenance treatment with anti-TNF-α drugs for refractory Crohn's disease  Gord Blackhouse, Nazila Assasi,
Induction and Maintenance Therapy With Infliximab for Children With Moderate to Severe Ulcerative Colitis  Jeffrey Hyams, Lakshmi Damaraju, Marion Blank,
Allergy to Surgical Implants
Volume 147, Issue 4, Pages e7 (October 2014)
Volume 133, Issue 2, Pages (August 2007)
Paula Borralho, Ana Vieira, João Freitas, Paula Chaves, Jorge Soares 
Long-term outcome after infliximab for refractory ulcerative colitis
M. Chaparro, P. Martínez-Montiel, M. Van Domselaar, F. Bermejo, J. L
Xian-rui Wu, Saurabh Mukewar, Ravi P. Kiran, Feza H
The usefulness of factor XIII levels in Crohn's disease
Genetic variants in autophagy-related genes and granuloma formation in a cohort of surgically treated Crohn's disease patients  Marko Brinar, Séverine.
Marc E. Schaefer, Jason T. Machan, David Kawatu, Christine R
Rapid improvement of refractory pyoderma gangrenosum with infliximab gel in a patient with ulcerative colitis  Niels Teich, Tobias Klugmann  Journal of.
Seth Lipka, Seymour Katz, Lev Ginzburg  Journal of Crohn's and Colitis 
Osteoporosis in inflammatory bowel disease
Endoscopic and Clinical Variables That Predict Sustained Remission in Children With Ulcerative Colitis Treated With Infliximab  Dan Turner, Anne M. Griffiths,
The Natural History of Corticosteroid Therapy for Ulcerative Colitis in Children  Jeffrey Hyams, James Markowitz, Trudy Lerer, Anne Griffiths, David Mack,
Antibiotic hypersensitivity in CF: Drug-induced life-threatening hemolytic anemia in a pediatric patient  Alma Chavez, Amir Mian, Amy M. Scurlock, Douglas.
Pediatric pulmonary Crohn's disease: More frequent than expected
“Ulcerative crepitus” — A case with subcutaneous emphysema and pneumomediastinum without colonic perforation or toxic megacolon in ulcerative colitis.
Ulrich Bonse-Geuking, Michael Kraus  Journal of Crohn's and Colitis 
Validation of a point-of-care desk top device to quantitate fecal calprotectin and distinguish inflammatory bowel disease from irritable bowel syndrome 
Increased Immune Reactivity Predicts Aggressive Complicating Crohn's Disease in Children  Marla C. Dubinsky, Subra Kugathasan, Ling Mei, Yoana Picornell,
Canadian cost-utility analysis of initiation and maintenance treatment with anti-TNF-α drugs for refractory Crohn's disease  Gord Blackhouse, Nazila Assasi,
Yield and cost effectiveness of mycobacterial infection detection using a simple IGRA- based protocol in UK subjects with inflammatory bowel disease suitable.
Genotyping should be considered the primary choice for pre-treatment evaluation of thiopurine methyltransferase function  Ulf Hindorf, Malin Lindqvist.
Yinghong Wang, Hua Gong, Rocio Lopez, Lei Lian, Ravi P. Kiran, Edy E
Surgical management of gluteal metastatic cutaneous Crohn's disease
Exclusive elemental diet impacts on the gastrointestinal microbiota and improves symptoms in patients with chronic pouchitis  S.D. McLaughlin, A. Culkin,
Clindamycin vs. first-generation cephalosporins for acute osteoarticular infections of childhood-a prospective quasi-randomized controlled trial  H. Peltola,
Bowel sonography in occlusive Crohn's disease
The role of in vitro interferonγ-release assay in differentiating intestinal tuberculosis from Crohn's disease in China  Yue Li, Li-fan Zhang, Xiao-qing.
Health-related quality of life in inflammatory bowel disease: Psychosocial, clinical, socioeconomic, and demographic predictors  Anilga Moradkhani, Linda.
Journal of the American College of Surgeons
Figure 1 Approximate timeline contrasting major historical events in the understanding of ulcerative colitis (red) and ... Figure 1 Approximate timeline.
Basavaraj Kerur, Jason T. Machan, Jason M. Shapiro, Carolina S
Corticosteroid Therapy in the Age of Infliximab: Acute and 1-Year Outcomes in Newly Diagnosed Children With Crohn’s Disease  James Markowitz, Jeffrey.
Increased Immune Reactivity Predicts Aggressive Complicating Crohn's Disease in Children  Marla C. Dubinsky, Subra Kugathasan, Ling Mei, Yoana Picornell,
Issue Highlights Clinical Gastroenterology and Hepatology
Presentation transcript:

C-reactive protein (CRP), erythrocyte sedimentation rate (ESR) or both C-reactive protein (CRP), erythrocyte sedimentation rate (ESR) or both? A systematic evaluation in pediatric ulcerative colitis  Dan Turner, David R. Mack, Jeffrey Hyams, Neal LeLeiko, Anthony Otley, James Markowitz, Yair Kasirer, Aleixo Muise, Cynthia H. Seow, Mark S. Silverberg, Wallace Crandall, Anne M. Griffiths  Journal of Crohn's and Colitis  Volume 5, Issue 5, Pages 423-429 (October 2011) DOI: 10.1016/j.crohns.2011.05.003 Copyright © 2011 European Crohn's and Colitis Organisation Terms and Conditions

Figure 1 Discriminant validity and best cutoff values to differentiate disease activity states of ESR (Fig. 1a) and C-reactive protein (Fig. 1b); both reflecting the combined derivation and validation cohorts. Disease activity states were defined by the PUCAI, as previously established.4 For simplicity, CRP values were truncated at 60mg/L and ESR at 120mm/h. Sens/Spec; sensitivity/specificity; AUROC; area under the ROC curve. Journal of Crohn's and Colitis 2011 5, 423-429DOI: (10.1016/j.crohns.2011.05.003) Copyright © 2011 European Crohn's and Colitis Organisation Terms and Conditions

Figure 2 Summary ROC curve (SROC) of the different combination cutoffs of ESR and/or CRP (see text). Journal of Crohn's and Colitis 2011 5, 423-429DOI: (10.1016/j.crohns.2011.05.003) Copyright © 2011 European Crohn's and Colitis Organisation Terms and Conditions

Figure 3 Rate of normal ESR (i.e. <23mm/h) and normal CRP (<2.5mg/L) values, stratified by disease activity states (measured by the PUCAI). Journal of Crohn's and Colitis 2011 5, 423-429DOI: (10.1016/j.crohns.2011.05.003) Copyright © 2011 European Crohn's and Colitis Organisation Terms and Conditions